Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Univo Pharmaceuticals Ltd
  6. News
  7. Summary
    UNVO   IL0010935588

UNIVO PHARMACEUTICALS LTD

(UNVO)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Can-Fite Biopharma Ltd and Univo Pharmaceuticals Ltd Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects

01/16/2020 | 07:00am EST

Can-Fite BioPharma Ltd. announced new findings in its collaboration with Univo Pharmaceuticals characterizing the effects of cannabinoids on diseases mediated through the A3 adenosine receptor (A3AR). Joint research shows that certain cannabinoid-based formulations exert a highly potent beneficial effect on diseased cells by binding to A3AR, and these findings present new opportunities for the development of cannabinoids in the treatment of a variety of diseases in which there is an overexpression of A3AR. Can-Fite filed a patent application titled “Cannabinoids for use in treating A3 adenosine receptor-associated conditions” based on these findings, and covering all the clinical indications in which A3AR is overexpressed. Can-Fite, a global leader in discovering and developing drugs which target A3AR, is collaborating with Univo Pharmaceuticals and utilizes its platform technology within the framework of this collaboration to develop cannabinoids for the treatment of large unmet medical needs.


ę S&P Capital IQ 2020
All news about UNIVO PHARMACEUTICALS LTD
11/30Univo Pharmaceuticals Ltd Reports Earnings Results for the Third Quarter and Nine Month..
CI
08/31Univo Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended June 30, 202..
CI
2020Can-Fite Biopharma Ltd. Announces New Pre-Clinical Findings in Connection with its On-G..
CI
2020Can-Fite Biopharma Ltd and Univo Pharmaceuticals Ltd Collaboration Result in Discovery ..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 5.994553 million in ..
CI
2019Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabin..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 2.499999 million in ..
CI
2019Univo Pharmaceuticals Ltd announced that it has received ILS 3 million in funding
CI
2019UNV Medicine LTD. announced that it has received ILS 6 million in funding from Hagag Gr..
CI
2018UNV-Medicine Signs New Deal with Israeli Cannabis Startup
CI
More news
Financials
Sales 2019 0,82  0,26  0,26 
Net income 2019 -11,8 M -3,77 M -3,77 M
Net cash 2019 22,8 M 7,29 M 7,29 M
P/E ratio 2019 -5,92x
Yield 2019 -
Capitalization 64,3 M 20,5 M 20,5 M
EV / Sales 2018 -
EV / Sales 2019 35 568 323x
Nbr of Employees -
Free-Float 59,6%
Chart UNIVO PHARMACEUTICALS LTD
Duration : Period :
Univo Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Golan Bitton Chief Executive Officer & Director
Moran Attar Yossef Chief Financial Officer
Chaim Hurvitz Chairman
Meital Ran Zohara Independent Director
Ahuva Shelly Harpaz Greenberg Independent External Director
Sector and Competitors
1st jan.Capi. (M$)
UNIVO PHARMACEUTICALS LTD-20.34%20
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888